Li et al. found that IGF2BP3 enhances the stability of lncRNA WEE2-AS1 in an m6A-dependent manner to promote GBM progression and attenuate the therapeutic sensitivity of dasatinib in glioma cells. Here, IGF2BP3 is linked to central nervous system cancer.